BACKGROUND: AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma. METHODS: Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model. RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]). This association differed markedly between lymphoma subtypes. Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997). Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment. CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART. The influence of cumulative HIV viremia may differ between lymphoma subtypes.
BACKGROUND:AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infectedpatients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma. METHODS: Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infectedpatients from different urban areas in Germany, were analyzed using a Cox proportional hazards model. RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]). This association differed markedly between lymphoma subtypes. Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997). Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment. CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART. The influence of cumulative HIV viremia may differ between lymphoma subtypes.
Authors: L Smyth; P V Browne; E Conneally; C Flynn; P Hayden; M Jeffers; D O'Brien; F Quinn; J Kelly; M Perera; G M Crotty; M Leahy; B Hennessy; F Jackson; M Ryan; E Vandenberghe Journal: Ir J Med Sci Date: 2015-04-07 Impact factor: 1.568
Authors: David J Riedel; Evelyn Ivy W Mwangi; Lori E Fantry; Carla Alexander; Mian B Hossain; C David Pauza; Robert R Redfield; Bruce L Gilliam Journal: AIDS Date: 2013-04-24 Impact factor: 4.177
Authors: Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag Journal: Am J Epidemiol Date: 2009-12-09 Impact factor: 4.897
Authors: Stephen T Wright; Jennifer Hoy; Brian Mulhall; Catherine C Oʼconnor; Kathy Petoumenos; Timothy Read; Don Smith; Ian Woolley; Mark A Boyd Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731